Literature DB >> 8702651

Eukaryotic expression of recombinant biglycan. Post-translational processing and the importance of secondary structure for biological activity.

A M Hocking1, R A Strugnell, P Ramamurthy, D J McQuillan.   

Abstract

Biglycan is a small chondroitin sulfate proteoglycan found in many tissues and is structurally related to decorin, fibromodulin, and lumican. The biological function of biglycan is poorly understood, although several studies have indicated interaction with other extracellular matrix components. We have initiated studies of structural and functional domains of biglycan by transient eukaryotic expression using the vaccinia virus/T7 bacteriophage expression system. A recombinant vaccinia virus, vBGN4 encoding the mature biglycan core protein as a polyhistidine fusion protein under control of the T7 phage promoter was expressed in HT-1080 cells and UMR106 cells. The structure of the recombinant biglycan secreted by these cells was defined by analyzing molecules labeled in the presence of [35S]sulfate, [3H]glucosamine, and [35S]methionine. Glycoforms of biglycan were separated by imidazole gradient elution, under non-denaturing conditions, and comprised: a large proteoglycan form substituted with two chondroitin sulfate chains of molecular mass approximately 34 kDa (HT-1080 cells) or approximately 40 kDa (UMR106 cells); a small proteoglycan form substituted with two chondroitin sulfate chains with a median molecular mass approximately 28 kDa; and a core protein form secreted devoid of glycosaminoglycan chains. All the glycoforms were substituted with two N-linked oligosaccharides, and the disaccharide composition of the two glycosaminoglycan populations were identical. Approximately 70% of the recombinant biglycan secreted by HT-1080 cells was substituted with chondroitin sulfate chains, whereas about 50% of the biglycan expressed by UMR106 cells was substituted with chondroitin sulfate chains. Infection with vBGN4 in both HT-1080 and UMR106 cells resulted in the production of approximately 10 mg of biglycan/10(9) cells per 24 h. The native recombinant biglycan was shown to bind to collagen type V and the complement protein, C1q. However, when the secondary structure of recombinant biglycan was disrupted by exposure to 4 M guanidine hydrochloride, the affinity for collagen type V was dramatically reduced. These data demonstrate the importance of secondary structure to the function of this small proteoglycan.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702651

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion.

Authors:  Kristin L Reigle; Gloria Di Lullo; Kevin R Turner; Jerold A Last; Inna Chervoneva; David E Birk; James L Funderburgh; Elizabeth Elrod; Markus W Germann; Charles Surber; Ralph D Sanderson; James D San Antonio
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

2.  LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis.

Authors:  John T Melchior; Janet K Sawyer; Kathryn L Kelley; Ramesh Shah; Martha D Wilson; Roy R Hantgan; Lawrence L Rudel
Journal:  J Lipid Res       Date:  2013-06-26       Impact factor: 5.922

3.  Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS.

Authors:  Mary Lynn Mercado; Alison R Amenta; Hiroki Hagiwara; Michael S Rafii; Beatrice E Lechner; Rick T Owens; David J McQuillan; Stanley C Froehner; Justin R Fallon
Journal:  FASEB J       Date:  2006-06-28       Impact factor: 5.191

4.  Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development.

Authors:  Michael S Rafii; Hiroki Hagiwara; Mary Lynn Mercado; Neung S Seo; Tianshun Xu; Tracey Dugan; Rick T Owens; Magnus Hook; David J McQuillan; Marian F Young; Justin R Fallon
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

5.  Modulation of canonical Wnt signaling by the extracellular matrix component biglycan.

Authors:  Agnes D Berendsen; Larry W Fisher; Tina M Kilts; Rick T Owens; Pamela G Robey; J Silvio Gutkind; Marian F Young
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

6.  Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor.

Authors:  D K Moscatello; M Santra; D M Mann; D J McQuillan; A J Wong; R V Iozzo
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

7.  Phenotypic characterization of epiphycan-deficient and epiphycan/biglycan double-deficient mice.

Authors:  S Nuka; W Zhou; S P Henry; C M Gendron; J B Schultz; T Shinomura; J Johnson; Y Wang; D R Keene; R Ramírez-Solis; R R Behringer; M F Young; M Höök
Journal:  Osteoarthritis Cartilage       Date:  2009-11-18       Impact factor: 6.576

Review 8.  Neoproteoglycans in tissue engineering.

Authors:  Amanda Weyers; Robert J Linhardt
Journal:  FEBS J       Date:  2013-03-07       Impact factor: 5.542

9.  Laser trabeculoplasty induces changes in the trabecular meshwork glycoproteome: a pilot study.

Authors:  Adriana Amelinckx; Maria Castello; Esdras Arrieta-Quintero; Tinthu Lee; Nelson Salas; Eleut Hernandez; Richard K Lee; Sanjoy K Bhattacharya; Jean-Marie A Parel
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

10.  Caveat emptor: for researchers, a rose will not smell sweet unless we know its composition.

Authors:  Josephine C Adams
Journal:  Biosci Rep       Date:  2017-05-11       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.